ArticleRheumatology (Oxford, England)2024
Multimorbidity in systemic lupus erythematosus in a population-based cohort: the Lupus Midwest Network.
Article in Rheumatology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.Arthritis research & therapy · 2024Trial
- Early SLE may follow a fast comorbidity/multimorbidity trajectory associated with flare burden and glucocorticoid exposure.RMD open · 2026Article
- Polypharmacy in Adults With Systemic Lupus Erythematosus.Arthritis care & research · 2026Article
- Article
- MCCs in adults with autoimmune and inflammatory rheumatic diseases: evidence to date and future directions.Therapeutic advances in musculoskeletal disease · 2026Review
- Association between disease duration and comorbidity burden in systemic lupus erythematosus: a multicentre study from Pakistan.Lupus science & medicine · 2025Article
- Review
- Association between social determinants of health and systemic lupus erythematosus: a nationally representative analysis of 2017-2021 data.Scientific reports · 2025Article
- Progressive Muscle Weakness and Dysphagia in Late-Onset Systemic Lupus Erythematosus: A Case Report.Cureus · 2025Article
- From Multimorbidity to Network Medicine in Patients with Rheumatic Diseases.Rheumatology and therapy · 2025Review
- Social Connections in Older Adults With Systemic Lupus Erythematosus: Patient Perspectives.ACR open rheumatology · 2025Article
- The Lived Experiences of Older Adults With Systemic Lupus Erythematosus: Patient Perspectives.The Journal of rheumatology · 2025Article
- Unveiling Ocular Manifestations in Systemic Lupus Erythematosus.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesThe objectives of this study were to assess the prevalence and incidence of multimorbidity and its association with the SLICC/ACR damage index (SDI) among patients with SLE.
methodsUsing prevalent and incident population-based cohorts of patients with SLE and their matched comparators, we assessed 57 chronic conditions. Chronic conditions were categorized as SDI-related or SDI-unrelated. Multimorbidity was defined as the presence of two or more chronic conditions. The prevalence of multimorbidity for both cohorts was compared using logistic regression. Cox models were used to examine the development of multimorbidity after SLE incidence.
resultsThe prevalent cohort included 449 patients with established SLE on 1 January 2015. They were three times more likely to have multimorbidity compared with non-SLE comparators [odds ratio (OR) 2.98, 95% CI 2.18-4.11]. The incident cohort included 270 patients with new-onset SLE. At SLE incidence, patients with SLE were more likely to have multimorbidity than comparators (OR 2.27, 95% CI 1.59-3.27). After incidence, the risk of developing multimorbidity was 2-fold higher among patients with SLE than among comparators [hazard ratio (HR) 2.11, 95% CI 1.59-2.80]. The development of multimorbidity was higher in patients with SLE based on SDI-related conditions (HR 2.91, 95% CI 2.17-3.88) than on SDI-unrelated conditions (HR 1.73, 95% CI, 1.32-2.26).
conclusionPatients with SLE had a higher burden of multimorbidity, even before the onset of the disease. The risk disparity continued after SLE classification and was also seen in a prevalent SLE cohort. Multimorbidity was driven both by SDI-related and unrelated conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.